Immunotherapy in the initial treatment of newly diagnosed cancer patients: Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer

Cancer Investigation

Volumn 28, Issue 1, 2010, Pages 46-53

  Shih, Ya Chen Tina ^a   Elting, Linda S ^a   Pavluck, Alexandre L ^b   Stewart, Andrew ^c   Halpern, Michael T ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c AMERICAN COLLEGE OF SURGEONS   (United States)

^d RTI INTERNATIONAL   (United States)

Author keywords

Health sciences research; Monoclonal antibodies; Outcomes research

Indexed keywords

BEVACIZUMAB; CETUXIMAB; RITUXIMAB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; COST BENEFIT ANALYSIS; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREND STUDY; UNITED STATES;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MALE; MODELS, ECONOMIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 72449132792     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900902783187     Document Type: Article

References (38)

1. Grabowski, H.; Cockburn, I.; Long, G. The market for follow-on biologics: how will it evolve? Health Affairs 2006, 25, 1291-1301.
2. Iglehart, J.K. Biotech drugs come of age; policymakers take notice. Health Affairs 2006, 25, 1202-1203.
3. Manheim, B.S., Jr.; Granahan, P.; Dow, K.J. "Follow-on biologics": ensuring continued innovation in the biotechnology industry. Health Affairs 2006, 25, 394-404.
4. Robinson, J.C. Insurers' strategies for managing the use and cost of biopharmaceuticals. Health Affairs 2006, 25, 1205-1217.
5. Nagle, P.C.; Lugo, T.F.; Nicita, C.A. Defining and characterizing the late-stage biopharmaceutical pipeline. AJMC 2003, 9, S124-S135.
6. American Cancer Society. Monoclonal Antibodies. Available from http://www.cancer.org/docroot/ETO/content/ETO 1 4X Monoclonal Antibody Therapy Passive Immunotherapy.asp (accessed August 12, 2008).
7. Reichert, J.M.; Valge-Archer, V.E. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007, 6, 349-356.
8. FDA. Drug@FDA. [accessd on October 24, 2008] Available at: http://www.accessdate.fda.gov/scripts/cder/drugsatfda/index.cfm.
9. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonoal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344, 783-792.
10. Murdoch, D.; Sager, J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 2008, 20, 104-111.
11. Stern, M.; Herrmann, R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol-Hematol 2005, 54, 11-29.
12. Reeder, C.E.; Gordon, D. Managing oncology costs. AJMC 2006, 12, S3-S16.
13. Hillner, B.E.; Smith, T.J. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol 2007, 25, 611-613.
14. Schrag, D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004, 351, 317-319.
15. Hornberger, J.C.; Best, J.H. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005, 103, 1644-1651.
16. Kurian, A.W.; Thompson, R.N.; Gaw, A.F.; Arai, S.; Ortiz, R.; Garber, A.M. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007, 25, 634-641.
17. Starling, N.; Tilden, D.; White, J.; Cunningham, D. Costeffectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007, 96, 206-212.
18. American College of Surgeons. National Cancer Data Base. Available from http://www.facs.org/cancer/ncdb/index.html (accessed June 15, 2008).
19. Halpern, M.T.; Bian, J.; Ward, E.M.; Schrag, N.M.; Chen, A.Y. Insurance status and stage of cancer at diagnosis among women with breast cancer. Cancer 2007, 110, 403-411.
20. Kennedy, B.J.; Fremgen, A.M.; Menck, H.R. The National Cancer Data Base report on Hodgkin's disease for 1985-1989 and 1990- 1994. Cancer 1998, 83, 1041-1047.
21. Stewart, A.K.; Bland, K.I.; McGinnis, L.S., Jr.; Morrow, M.; Eyre, H.J. Clinical highlights from the National Cancer Data Base, 2000. CA: Cancer J Clin 2000, 50, 171-183. (Pubitemid 30417326)
22. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society, 2007.
23. American College of Surgeons. FORDS: Facility Oncology Registry Data Standards 2007. Available from http://www.facs.org/cancer/coc/fords/2007/ fordscorrected0707.pdf (accessed June 20, 2008).
24. Lockyer, C.R.; Gillatt, D.A. BCG immunotherapy for superficial bladder cancer. J R Soc Med 2001, 94, 119-123.
25. Jazirehi, A.R.; Gan, X.H.; De Vos, S.; Emmanouilides, C.; Bonavida, B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003, 2, 1183-1193.
26. CMS 2008 ASP Drug Pricing Files, October 2008. Available from http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/01a 2008aspfiles.asp#TopOfPage (accessed December 21, 2008).
27. Kabbinavar, F.F.; Hambleton, J.; Mass, R.D.; Hurwitz, H.I.; Bergsland, E.; Sarkar, S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23, 3706-3712.
28. American Cancer Society. Cancer Facts and Figures 2004. Atlanta, GA: American Cancer Society, 2004.
29. Adams, G.P.;Weiner, L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23, 1147-1157.
30. Kirkwood, J.M.; Ibrahim, J.G.; Sosman, J.A.; Sondak, V.K.; Agarwala, S.S.; Ernstoff, M.S.; Rao, U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19, 2370-2380.
31. Porta, C.; Paglino, C.; Imarisio, I.; Bonomi, L. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. Sci World J 2007, 7, 837-849.
32. Van Cutsem, E.; Peeters, M.; Verslype, C.; Filez, L.; Haustermans, K.; Janssens, J. The medical treatment of colorectal cancer: actual status and new developments. Hepatogastroenterology 1999, 46, 709-716. (Pubitemid 29224725)
33. Lin, A.; Rugo, H.S. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol 2007, 8, 47-60.
34. Chen, A.Y.; Halpern, M.T.; Schrag, N.M.; Stewart, A.; Leitch, M.; Ward, E. Disparities and trends in receipt of sentinel lymph node biopsy among early stage female breast cancer patients. J Natl Cancer Inst 2008, 100, 462-474.
35. Richardson, L.C.; Tian, L.; Voti, L.; Hartzema, A.G.; Reis, I.; Fleming, L.E.; Mackinnon, J. The roles of teaching hospitals, insurance status, and race/ethnicity in receipt of adjuvant therapy for regional-stage breast cancer in Florida. Am J Public Health 2006, 96, 160-166.
36. Ward, E.; Halpern, M.T.; Schrag, N.; Cokkinides, V.; Desantis, C.; Bandi, P.; Siegel, R.; Stewart, A.; Jemal, A. Association of insurance with cancer care utilization and outcomes. CA: Cancer J Clin 2008, 58, 9-31.
37. Schoen, C.; Doty, M.M.; Collins, S.R.; Holmgren, A.L. Insured but not protected: how many adults are underinsured? Health Affairs 2005 (Suppl) Web Exclusives: W5-289-W5-302.
38. Shih, Y.C.T. Economic of cancer in the elderly population. Institute of Medicine Cancer in Elderly Population: Workshop Proceeding. Washington, DC: The National Academies Press, 2007.